Post on 25-Dec-2015
Patricia Brown, PhD, ARNP
Where Are We Heading?
New ADTs This Decade
o Oleptro (extended release Trazodone)
2010
o Viibryd (Vilazodone) 2011
o Fetzima (Levomilnacipran) 2013
o Brintellix (Vortioxetine) 2013
313 Psychiatric Drugs in Developmento Dementia (90 Investigational Products)
o Depression (71 Investigational Products )
o Schizophrenia (54 Investigational Products)
o Anxiety Disorders (38 Investigational Products)
The NIMH Priority for Psychiatric Drug Development:
o Rapid acting antidepressant
o Generation of antipsychotics which assists with cognition
o Autism medication which addresses pro-social components
Ketamine infusions for treatment resistant depression
ALKS 5461
Blocking the Kappa Receptor
o When Dynorphin are released=Depression
o Blocking this stimulates ADT action
o High levels of Dynorphin block glutamate.
Glutamate is thought to prevent
neuroplasticity and prevent poor learning
abilities and prevent learned helplessness.
AVP-786 is a modified dextromethorphan which is an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter
As of Jan 2015 There Are 5 New Anxiety Investigation Productso Most popular drug still are
BDZs
o The goal –to find as efficacious a drug without the sedative side effects or addictive potential
Aloradine (PH94B)
o A vomeropherine neuroactive steriod drug
o Under development as a nasal spray formulation
o For the acute treatment of social anxiety disorder in women.
B-GOSo Galacto-oligosaccharides belong to
the group of prebiotics.
o Prebiotics are defined as non-digestible food ingredients that beneficially affect the host by stimulating the growth and/or activity of beneficial bacteria in the colon.
IW-2143 (BNC210)
S32212o a novel serotonin type 2C receptor inverse
agonist/α2-adrenoceptor antagonist and potential antidepressant
SL-651,498
o a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder
o an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.
Translocator Protein (18 kD)o Peripheral
benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state.
TMS
Over 30 New Medications in Development for Schizophrenia May 2014
Caripazine (RGH-188)o D2, D3 antagonist
LY2140023o Prodrug for an
mGluR2/3 agonisto Phase three
development
BrexpiprazoleOPC-34712o a novel D2 dopamine
partial agonist
What is in the works for Cognition and social skill development in autism
Autism Drugs in Developmento AT001 ( uoxetine rapid dissolve) ORPHAN DRUGo CM-AT Rye, NY (Fast Track) application submitted
www.curemark.como CNDO-201 (Trichuris suis ova) Coronado Biosciences
autism Phase II www.coronadobiosciences.como Memantine Forest Laboratories Phase II completedo RG7314 (vasopressin-1 receptor antagonist)o Autism Phase IIo Syntocinon nasal spray Retrophin Arbaclofen or STX209,
is a derivative of the FDA-approved drug, baclofen
NIMH Strategic Objectiveso Promote discovery in the brain and
behavioral sciences to fuel research on the causes of mental disorders
o Chart mental illness trajectories to determine when, where and how to intervene
o Develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illnesses
o Strengthen the public health impact of NIMH-supported research
o Thank You for Your Attention!
Referenceso Huda Akil, Sydney Brenner, Eric Kandel, Kenneth S.
Kendler, Mary-Claire King, Edward Scolnick, James D. Watson, and Huda Y. Zoghbi; The Future of Psychiatric Research: Genomes and Neural Circuits. Science 26 March 2010: 1580-1581.
o Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg, Aaron L. Schacht ; How to improve R&D productivity: the pharmaceutical industry's grand challenge .Nature Reviews Drug Discovery 9, 203-214 (19 February 2010)